InsiderTrades

Form 4 for BIIB Biogen

Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001127602-23-029445 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-12-12 2023-12-08 BIIB Singhal Priya Head of Development M - OptEx $0.00 +426 3,780 +13% $0
D 2023-12-12 2023-12-08 BIIB Singhal Priya Head of Development F - Tax $239.29 -206 3,574 -5% -$49.3K
D 2023-12-12 2023-12-11 BIIB Singhal Priya Head of Development S - Sale+OE $248.00 -110 3,464 -3% -$27.3K
D 2023-12-12 2023-12-08 BIIB Singhal Priya Head of Development M - OptEx $0.00 -426 426 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-12-08 M A 426 $0.00 3,780.09 D — —
2 Common Common Stock 2023-12-08 F D 206 $239.29 3,574.09 D — —
3 Common Common Stock 2023-12-11 S D 110 $248.00 3,464.09 D — —
4 Derivative Restricted Stock Unit 2023-12-08 M D 426 $0.00 426 D $0.00 · — to 2024-12-08 426 Common Stock (F1) This award was granted to the reporting person on December 8, 2021 and will vest in three equal installments on each anniversary of the grant date.